243 related articles for article (PubMed ID: 22541618)
81. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
[TBL] [Abstract][Full Text] [Related]
82. Advances in the diagnosis and treatment of eosinophilia.
Helbig G
Curr Opin Hematol; 2014 Jan; 21(1):3-7. PubMed ID: 24322486
[TBL] [Abstract][Full Text] [Related]
83. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
84. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
85. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.
Peters MC; Mekonnen ZK; Yuan S; Bhakta NR; Woodruff PG; Fahy JV
J Allergy Clin Immunol; 2014 Feb; 133(2):388-94. PubMed ID: 24075231
[TBL] [Abstract][Full Text] [Related]
86. Dupilumab in persistent asthma.
Wenzel SE; Wang L; Pirozzi G
N Engl J Med; 2013 Sep; 369(13):1276. PubMed ID: 24066755
[No Abstract] [Full Text] [Related]
87. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.
Jovani M; Fiorino G; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1444-52. PubMed ID: 23746199
[TBL] [Abstract][Full Text] [Related]
88. Anti-interleukin-13 antibody therapy for asthma: one step closer.
Corren J
Eur Respir J; 2013 Feb; 41(2):255-6. PubMed ID: 23370798
[No Abstract] [Full Text] [Related]
89. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.
Walsh GM
Biologics; 2013; 7():7-11. PubMed ID: 23326187
[TBL] [Abstract][Full Text] [Related]
90. Human eosinophils release IL-1ß and increase expression of IL-17A in activated CD4+ T lymphocytes.
Esnault S; Kelly EA; Nettenstrom LM; Cook EB; Seroogy CM; Jarjour NN
Clin Exp Allergy; 2012 Dec; 42(12):1756-64. PubMed ID: 23181791
[TBL] [Abstract][Full Text] [Related]
91. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.
Strati P; Cortes J; Faderl S; Kantarjian H; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):287-91. PubMed ID: 23123105
[TBL] [Abstract][Full Text] [Related]
92. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
93. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
94. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
95. Targeting key proximal drivers of type 2 inflammation in disease.
Gandhi NA; Bennett BL; Graham NM; Pirozzi G; Stahl N; Yancopoulos GD
Nat Rev Drug Discov; 2016 Jan; 15(1):35-50. PubMed ID: 26471366
[TBL] [Abstract][Full Text] [Related]
96. Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms.
Massironi S; Mulinacci G; Gallo C; Elvevi A; Danese S; Invernizzi P; Vespa E
Cells; 2023 Oct; 12(20):. PubMed ID: 37887317
[TBL] [Abstract][Full Text] [Related]
97. Eosinophil Phenotypes Are Functionally Regulated by Resolvin D2 during Allergic Lung Inflammation.
Brüggemann TR; Peh HY; Tavares LP; Nijmeh J; Shay AE; Rezende RM; Lanser TB; Serhan CN; Levy BD
Am J Respir Cell Mol Biol; 2023 Dec; 69(6):666-677. PubMed ID: 37552821
[TBL] [Abstract][Full Text] [Related]
98. Eosinophilic esophagitis: Immune mechanisms and therapeutic targets.
Khokhar D; Marella S; Idelman G; Chang JW; Chehade M; Hogan SP
Clin Exp Allergy; 2022 Oct; 52(10):1142-1156. PubMed ID: 35778876
[TBL] [Abstract][Full Text] [Related]
99. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.
Singh D; Fuhr R; Bird NP; Mole S; Hardes K; Man YL; Cahn A; Yancey SW; Pouliquen IJ
Br J Clin Pharmacol; 2022 Feb; 88(2):702-712. PubMed ID: 34292606
[TBL] [Abstract][Full Text] [Related]
100. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
